Crinetics Pharmaceuticals, Inc. announced that the late-breaking abstracts accepted for presentation at the Endocrine Society?s annual meeting (ENDO 2024) were released earlier than the previously announced embargoed date. The abstract for the Phase 2, open-label study of atumelnant (CRN04894), in Congenital Adrenal Hyperplasia contained summary data for four subjects at the time of submission. The company plans to present additional data from a total of six subjects in cohort 1 and additional subjects in cohort 2 at ENDO 2024.